416 related articles for article (PubMed ID: 8923032)
1. Mechanistic considerations in the evaluation of chemopreventive data.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC
IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic considerations in chemopreventive drug development.
Kelloff GJ; Boone CW; Steele VE; Fay JR; Lubet RA; Crowell JA; Sigman CC
J Cell Biochem Suppl; 1994; 20():1-24. PubMed ID: 7616736
[TBL] [Abstract][Full Text] [Related]
3. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
4. [Preventive medicine: biomonitoring and chemoprevention].
Tompa A; Szende B
Magy Onkol; 2002; 46(2):147-53. PubMed ID: 12202894
[TBL] [Abstract][Full Text] [Related]
5. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
6. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
7. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
8. The role of chemoprevention in cancer control.
Greenwald P; Kelloff GJ
IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016
[TBL] [Abstract][Full Text] [Related]
9. Micronutrients as chemopreventive agents.
Reddy BS
IARC Sci Publ; 1996; (139):221-35. PubMed ID: 8923033
[TBL] [Abstract][Full Text] [Related]
10. Overview of mechanisms of cancer chemopreventive agents.
De Flora S; Ferguson LR
Mutat Res; 2005 Dec; 591(1-2):8-15. PubMed ID: 16107270
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay.
Arnold JT; Wilkinson BP; Sharma S; Steele VE
Cancer Res; 1995 Feb; 55(3):537-43. PubMed ID: 7834622
[TBL] [Abstract][Full Text] [Related]
12. Progress in clinical chemoprevention.
Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of short-term test data: implications for assessment of chemopreventive activity.
Waters MD; Stack HF; Jackson MA; Brockman HE
IARC Sci Publ; 1996; (139):313-32. PubMed ID: 8923041
[TBL] [Abstract][Full Text] [Related]
14. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models.
Kwon KH; Barve A; Yu S; Huang MT; Kong AN
Acta Pharmacol Sin; 2007 Sep; 28(9):1409-21. PubMed ID: 17723174
[TBL] [Abstract][Full Text] [Related]
15. Data evaluation as a contribution to cancer prevention.
Stewart BW
IARC Sci Publ; 1996; (139):303-12. PubMed ID: 8923040
[TBL] [Abstract][Full Text] [Related]
16. Cancer chemoprevention with garlic and its constituents.
Shukla Y; Kalra N
Cancer Lett; 2007 Mar; 247(2):167-81. PubMed ID: 16793203
[TBL] [Abstract][Full Text] [Related]
17. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
Sanner T; Dybing E
Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
[TBL] [Abstract][Full Text] [Related]
18. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
19. Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents.
Izzotti A; Camoirano A; Cartiglia C; Grubbs CJ; Lubet RA; Kelloff GJ; De Flora S
Cancer Res; 1999 Sep; 59(17):4285-90. PubMed ID: 10485473
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
